Clinical Trial

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Study acronym: IMPACT STREAM
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-06-10; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting 2025-01-24
Trial Details
NCT Number NCT06459024
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborators: Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Conditions Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Enrollment 4,000 participants
Start Date 2024-06-28
Primary Completion 2032-07 (estimated)
Study Completion 2032-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-14